MEP47408A - Hfa-suspension formulations containing an anticholinergic - Google Patents

Hfa-suspension formulations containing an anticholinergic

Info

Publication number
MEP47408A
MEP47408A MEP-474/08A MEP47408A MEP47408A ME P47408 A MEP47408 A ME P47408A ME P47408 A MEP47408 A ME P47408A ME P47408 A MEP47408 A ME P47408A
Authority
ME
Montenegro
Prior art keywords
hfa
anticholinergic
formulations containing
suspension formulations
suspension
Prior art date
Application number
MEP-474/08A
Other languages
Croatian (hr)
Inventor
Christel Schmelzer
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28050989&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP47408(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MEP47408A publication Critical patent/MEP47408A/en
Publication of ME00247B publication Critical patent/ME00247B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Pronalazak se odnosi na formulaciju, sa potisnim gasom, suspenzije, kristalnog monohidrata (1α, 2β, 4β, 5α, 7β)-7-[(hidfroksidi-2-tienilacetil)oksi]-9,9-dimetil-3-oksa-9-azoniatriciklo[3.3.1.02,4]nonan-bromida.The invention relates to the formulation, with propellant, of a suspension, of crystalline monohydrate (1α, 2β, 4β, 5α, 7β) -7 - [(hydroxides-2-thienylacetyl) oxy] -9,9-dimethyl-3-oxa-9 -azoniatricyclo [3.3.1.02,4] nonan bromide.

MEP-2008-474A 2002-03-28 2003-03-20 Hfa-suspension formulations containing an anticholinergic ME00247B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10214263A DE10214263A1 (en) 2002-03-28 2002-03-28 HFA suspension formulations containing an anticholinergic
PCT/EP2003/002898 WO2003082252A1 (en) 2002-03-28 2003-03-20 Hfa-suspension formulations containing an anticholinergic

Publications (2)

Publication Number Publication Date
MEP47408A true MEP47408A (en) 2011-02-10
ME00247B ME00247B (en) 2011-05-10

Family

ID=28050989

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-474A ME00247B (en) 2002-03-28 2003-03-20 Hfa-suspension formulations containing an anticholinergic

Country Status (27)

Country Link
EP (2) EP1492513B1 (en)
JP (1) JP4480401B2 (en)
KR (1) KR101066801B1 (en)
CN (1) CN1329023C (en)
AT (1) ATE339953T1 (en)
AU (1) AU2003209743B2 (en)
BR (1) BR0308764A (en)
CA (1) CA2479640C (en)
CY (1) CY1105543T1 (en)
DE (2) DE10214263A1 (en)
DK (1) DK1492513T3 (en)
EA (1) EA007239B1 (en)
EC (1) ECSP045321A (en)
ES (1) ES2273020T3 (en)
HK (1) HK1079091A1 (en)
HR (1) HRP20040889B1 (en)
IL (2) IL163697A0 (en)
ME (1) ME00247B (en)
MX (1) MXPA04009337A (en)
NO (1) NO20044005L (en)
NZ (1) NZ536043A (en)
PL (1) PL371296A1 (en)
PT (1) PT1492513E (en)
RS (1) RS52178B (en)
UA (1) UA78557C2 (en)
WO (1) WO2003082252A1 (en)
ZA (1) ZA200405638B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1809243T5 (en) 2004-07-02 2022-12-27 Boehringer Ingelheim International Gmbh Aerosol suspension formulations containing tg 227 ea as a propellant
TWI396541B (en) * 2005-10-10 2013-05-21 Boehringer Ingelheim Int Novel combinations of medicaments for the treatment of respiratory diseases
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
GB201200504D0 (en) * 2011-12-19 2012-02-22 Teva Branded Pharmaceutical Prod R & D Inc An inhaler
EP2705838A1 (en) * 2012-09-06 2014-03-12 Xspray Microparticles Ab Tiotropium preparations
WO2014064410A2 (en) * 2012-10-23 2014-05-01 Cipla Limited Pharmaceutical composition
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
CN107056629B (en) * 2017-04-27 2019-04-30 河北科技大学 A kind of preparation method of anhydrous halogenation choline and its derivative monocrystalline

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
PT1102579E (en) * 1998-08-04 2003-07-31 Jago Res Ag MEDICINAL AEROSOL FORMULATIONS
DZ2947A1 (en) * 1998-11-25 2004-03-15 Chiesi Farma Spa Pressure metered dose inhaler.
DE19921693A1 (en) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
IT1317846B1 (en) * 2000-02-22 2003-07-15 Chiesi Farma Spa FORMULATIONS CONTAINING AN ANTICOLINERGIC DRUG FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE BRONCOPNEUMOPATHY.
GB0009605D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
MEP40008A (en) * 2000-10-12 2011-02-10 Boehringer Ingelheim Pharma Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
AU2002210575A1 (en) * 2000-10-31 2002-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel medicament compositions based on anticholinergics and corticosteroids
DE10056104A1 (en) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Drug compositions useful for treatment of respiratory diseases, especially asthma and chronic obstructive pulmonary disease comprises tiotropium salts and salmeterol salts

Also Published As

Publication number Publication date
EP1695701A2 (en) 2006-08-30
AU2003209743B2 (en) 2008-03-06
EP1492513A1 (en) 2005-01-05
IL163697A0 (en) 2005-12-18
AU2003209743A1 (en) 2003-10-13
ZA200405638B (en) 2005-07-27
ME00247B (en) 2011-05-10
EP1695701B1 (en) 2015-01-07
ECSP045321A (en) 2005-01-28
DK1492513T3 (en) 2006-12-18
ES2273020T3 (en) 2007-05-01
EA007239B1 (en) 2006-08-25
ATE339953T1 (en) 2006-10-15
PT1492513E (en) 2006-12-29
EA200401190A1 (en) 2005-04-28
DE10214263A1 (en) 2003-10-16
DE50305118D1 (en) 2006-11-02
EP1492513B1 (en) 2006-09-20
CN1329023C (en) 2007-08-01
WO2003082252A1 (en) 2003-10-09
EP1695701A3 (en) 2010-04-28
IL163697A (en) 2011-03-31
PL371296A1 (en) 2005-06-13
YU85904A (en) 2006-08-17
HRP20040889B1 (en) 2012-11-30
JP2005529087A (en) 2005-09-29
NZ536043A (en) 2005-09-30
CA2479640C (en) 2010-09-28
BR0308764A (en) 2005-01-11
UA78557C2 (en) 2007-04-10
NO20044005L (en) 2004-10-05
KR101066801B1 (en) 2011-09-22
CY1105543T1 (en) 2010-07-28
HRP20040889A2 (en) 2004-12-31
RS52178B (en) 2012-10-31
MXPA04009337A (en) 2005-01-25
KR20040098031A (en) 2004-11-18
CN1642534A (en) 2005-07-20
JP4480401B2 (en) 2010-06-16
CA2479640A1 (en) 2003-10-09
HK1079091A1 (en) 2006-03-31

Similar Documents

Publication Publication Date Title
MEP40608A (en) Method for producing the anticholinergic agent tiotropium bromide
EA200401142A1 (en) MICRONIZED CRYSTALLINE TIOTROPYBROMID
MEP62008A (en) Crystalline anticholinergic, method for its production, and use thereof in the production of a drug
MEP40008A (en) Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
CY1105543T1 (en) ANTICHOLINERGIC CONTAINING HFA SUSPENSION PREPARATIONS
WO2002072095A3 (en) Tiotropium salts for treating inflammatory diseases
DK1401837T3 (en) Purine derivatives as A2B adenosine receptor antagonists
MEP47308A (en) Hfa-suspension formulation of an anhydrate
MXPA04009162A (en) Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5).
MX9301824A (en) HYDROXYLATED METABOLITES AND BOXAZOSIN DERIVATIVES AS ANTI-ATEROSCLEROTIC AGENTS.
ECSP034921A (en) CRYSTALLINE ANTI-POLYNERGIC, METHOD FOR PRODUCTION, AND USE OF THE SAME IN THE PRODUCTION OF A DRUG
FI896173A0 (en) Process for the preparation of a therapeutically useful 1- (5-amino-7-phenyl / 1,2,4 / triazolo [1,5-c] pyrimidin-5-yl) -1,2-ethanediol